A detailed history of Private Advisor Group, LLC transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Private Advisor Group, LLC holds 47,413 shares of AVXL stock, worth $324,304. This represents 0.0% of its overall portfolio holdings.

Number of Shares
47,413
Previous 42,971 10.34%
Holding current value
$324,304
Previous $181,000 48.62%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 22, 2024

BUY
$4.11 - $7.04 $18,256 - $31,271
4,442 Added 10.34%
47,413 $269,000
Q2 2024

Aug 05, 2024

BUY
$3.39 - $5.02 $155 - $230
46 Added 0.11%
42,971 $181,000
Q1 2024

Apr 30, 2024

BUY
$4.55 - $6.75 $8,849 - $13,128
1,945 Added 4.75%
42,925 $218,000
Q4 2023

Feb 06, 2024

SELL
$5.04 - $9.95 $9,324 - $18,407
-1,850 Reduced 4.32%
40,980 $381,000
Q3 2023

Nov 02, 2023

BUY
$6.55 - $9.37 $73,032 - $104,475
11,150 Added 35.2%
42,830 $280,000
Q2 2023

Aug 09, 2023

SELL
$7.66 - $9.5 $57,450 - $71,250
-7,500 Reduced 19.14%
31,680 $257,000
Q1 2023

May 10, 2023

SELL
$8.32 - $11.75 $654,784 - $924,725
-78,700 Reduced 66.76%
39,180 $335,000
Q4 2022

Jan 18, 2023

SELL
$7.65 - $14.43 $128,520 - $242,424
-16,800 Reduced 12.47%
117,880 $0
Q3 2022

Oct 14, 2022

SELL
$8.9 - $12.86 $461,020 - $666,148
-51,800 Reduced 27.78%
134,680 $1.39 Million
Q2 2022

Jul 13, 2022

BUY
$7.31 - $12.84 $462,174 - $811,809
63,225 Added 51.3%
186,480 $1.87 Million
Q1 2022

May 12, 2022

BUY
$9.74 - $17.69 $1.2 Million - $2.18 Million
123,255 New
123,255 $1.52 Million
Q3 2020

Nov 02, 2020

SELL
$3.8 - $5.0 $11,400 - $15,000
-3,000 Closed
0 $0
Q2 2020

Aug 17, 2020

BUY
$2.62 - $5.2 $7,860 - $15,600
3,000 New
3,000 $15,000

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $533M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Private Advisor Group, LLC Portfolio

Follow Private Advisor Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Private Advisor Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Private Advisor Group, LLC with notifications on news.